Presentation to JP Morgan Healthcare Conference

See the latest presentation by TFS subsidiary Santalis Pharmaceuticals to the JP Morgan Healthcare Conference held in San Francisco.
READ PRESENTATION

Highlights
Santalis is uniquely situated as a dermatology-focused pharmaceutical company:

  • Proprietary drug substance with sole source supply and significant market protection.

  • Broad biological activity with both disease-specific targets (il-4, il-17, pde4, etc.) and multiple mechanisms of action - applicable to numerous clinical applications.

  • Wide range of high value target clinical indications, many of which have no current RX treatment.

  • Portfolio of late stage clinicals - numerous shots on goal.

  • Diversification into global otc product markets.

Based on comparable valuations for companies at this stage of development, Santalis’ attributes would suggest a valuation in the us$300-$500m range, with significant upside upon progress of its clinical trials through Phase 3 and registration stages.